BC
ANTH

Broadfin Capital’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Broadfin Capital’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-144,334
Closed -$3.64M – 75
2016
Q3 		$3.64M Hold
144,334
– – 0.33% 60
2016
Q2 		$3.57M Hold
144,334
– – 0.35% 53
2016
Q1 		$4.18M Hold
144,334
– – 0.4% 53
2015
Q4 		$5.36M Hold
144,334
– – 0.33% 63
2015
Q3 		$7.03M Sell
144,334
-26,973
-16% -$1.88M 0.39% 59
2015
Q2 		$11.8M Sell
171,307
-131,250
-43% -$6.08M 0.63% 42
2015
Q1 		$10.8M Buy
302,557
+79,580
+36% +$2.36M 0.84% 34
2014
Q4 		$2.82M Buy
222,977
+60,274
+37% +$875K 0.25% 68
2014
Q3 		$2.5M Buy
162,703
+66,912
+70% +$1.41M 0.26% 65
2014
Q2 		$2.6M Hold
95,791
– – 0.25% 65
2014
Q1 		$2.57M Hold
95,791
– – 0.25% 77
2013
Q4 		$2.35M Buy
95,791
+6,729
+8% +$173K 0.31% 51
2013
Q3 		$2.86M Buy
89,062
+23,437
+36% +$727K 0.51% 43
2013
Q2 		$1.95M Buy
+65,625
New +$2.45M 0.38% 43

Other funds holding ANTH

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Broadfin Capital's ANTH Position: Q4 2016 in Review

Broadfin Capital sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2016, closing a stake of 144,334 shares — an estimated $3.64M sold.

Broadfin Capital first reported a position in ANTH in Q2 2013 and held it in 14 quarters. The position peaked at $11.8M in Q2 2015. 72 funds tracked by Wall St. Rank hold ANTH as of Q4 2016.

  • Broadfin Capital reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Broadfin Capital sold 144,334 Anthera Pharmaceuticals, Inc. shares in Q4 2016, an estimated $3.64M.
  • Broadfin Capital first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 14 quarters.
  • Broadfin Capital's Anthera Pharmaceuticals, Inc. position peaked at $11.8M in Q2 2015.
  • 72 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2016.

Based on Broadfin Capital's 13F filing for Q4 2016, filed 14 Feb 2017.